CLINICAL CASES OF WORSENING OR NEWLY DEVELOPED PUSTULOSE PSORIASIS IN PATIENTS TREATED WITH ADALIMUMAB AND LEFLUNOMIDE

被引：0
|
作者：
Popova, V. [1 ]
Batalov, A. [1 ]
Vazhev, Z. [2 ]
Peshev, J. [3 ]
Geneva-Popova, M. [4 ]
Ronchev, Y. [1 ]
Peeva, J. [5 ]
Kraev, K. [1 ]
Ivanova, M. [1 ]
Ivanov, A. [2 ]
机构：
[1] Med Univ Plovdiv, UMHAT Kaspela, Dept Rheumatol, Plovdiv, Bulgaria
[2] Med Univ Plovdiv, UMHAT Sv Georgi, Dept Cardiosurg, Plovdiv, Bulgaria
[3] Med Univ Plovdiv, Dept Gen & Clin Pathol, Plovdiv, Bulgaria
[4] Med Univ Plovdiv, Dept Rheumatol, Plovdiv, Bulgaria
[5] Med Univ Plovdiv, Dept Publ Hlth, Plovdiv, Bulgaria
来源：
OSTEOPOROSIS INTERNATIONAL | 2017年 / 28卷
关键词：
LESIONS;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P395
引用
收藏
页码：S270 / S271
页数：2
相关论文
共 50 条
  • [1] Paradoxical psoriasis developed in 8 HS patients treated with adalimumab
    Liakou, Aikaterini
    Agiasofitou, Efthymia
    Tsiogka, Aikaterini
    Bonatsou, Konstantina
    Papadakis, Marios
    Papazisi, Maria
    Vladeni, Soultana
    Katoulis, Alexandros
    Stratigos, Alexandros
    Rigopoulos, Dimitrios
    Kontochristopoulos, Georgios
    EXPERIMENTAL DERMATOLOGY, 2022, 31 : 107 - 108
  • [2] Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn’s disease
    Hirotsugu Imaeda
    Kenichiro Takahashi
    Takehide Fujimoto
    Shigeki Bamba
    Tomoyuki Tsujikawa
    Masaya Sasaki
    Yoshihide Fujiyama
    Akira Andoh
    Journal of Gastroenterology, 2014, 49 : 100 - 109
  • [3] Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease
    Imaeda, Hirotsugu
    Takahashi, Kenichiro
    Fujimoto, Takehide
    Bamba, Shigeki
    Tsujikawa, Tomoyuki
    Sasaki, Masaya
    Fujiyama, Yoshihide
    Andoh, Akira
    JOURNAL OF GASTROENTEROLOGY, 2014, 49 (01) : 100 - 109
  • [4] Improvement of Quality of Life in Patients with Psoriasis Being Treated with Adalimumab
    Doerfler, F.
    Schoeberl, A.
    Amon, U.
    AKTUELLE DERMATOLOGIE, 2010, 36 (8-9) : 305 - 308
  • [5] Drug concentration and antidrug antibodies in patients with psoriasis treated with adalimumab or etanercept
    Gyldenlove, M.
    Zachariae, C.
    Jensen, P.
    Griehsel, H.
    Stahle, M.
    Skov, L.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (12) : E518 - E519
  • [6] Adalimumab treats psoriasis in patients previously treated with etanercept: A case series
    Yamauchi, Paul S.
    Mau, Nicole
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2009, 61 (01) : 158 - 160
  • [7] Weight and demographic characteristics of psoriasis patients treated with adalimumab, etanercept, or ustekinumab
    Meyer, Roxanne
    Yeaw, Jason
    Zhang, Mingliang
    Hines, Dionne
    Wade, Ron
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB257 - AB257
  • [8] Predictors of Clinical Worsening in Patients with PAH Treated with Bosentan
    Vizza, D. C.
    Badagliacca, R.
    Poscia, R.
    Crescenzi, E.
    Gambardella, C.
    Nona, A.
    Fedele, F.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2009, 28 (02): : S156 - S157
  • [9] Characteristics of patients newly initiating ustekinumab, adalimumab, secukinumab, apremilast or methotrexate for plaque psoriasis
    Lee, Seina
    Carroll, Charlotte
    Pericone, Christopher
    Tunceli, Ozgur
    Fakharzadeh, Steve
    Feldman, Steve
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2017, 76 (06) : AB66 - AB66
  • [10] Anti-adalimumab and anti-infliximab antibodies developed in psoriasis vulgaris patients reduced the efficacy of biologics: Report of two cases
    Matsumoto, Yuka
    Maeda, Tatsuo
    Tsuboi, Ryoji
    Okubo, Yukari
    JOURNAL OF DERMATOLOGY, 2013, 40 (05): : 389 - 392
12345